Open AccessDENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy
Author(s) -
Miyo Masaaki,
Kato Takeshi,
Nakamura Yoshiaki,
Taniguchi Hiroya,
Takahashi Yusuke,
Ishii Masayuki,
Okita Kenji,
Ando Koji,
Yukami Hiroki,
Mishima Saori,
Yamazaki Kentaro,
Kotaka Masahito,
Watanabe Jun,
Oba Koji,
Aleshin Alexey,
Billings Paul R.,
Rabinowitz Matthew,
Kotani Daisuke,
Oki Eiji,
Takemasa Ichiro,
Mori Masaki,
Yoshino Takayuki
Publication year - 2022
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.15226
Subject(s) - medicine , colorectal cancer , dissection (medical) , pathological , lymph node , stage (stratigraphy) , biopsy , risk stratification , oncology , surgery , general surgery , radiology , cancer , paleontology , biology
According to the current international guidelines, high‐risk patients diagnosed with pathological T1 (pT1) colorectal cancer (CRC) who underwent complete local resection but may have risk of developing lymph node metastasis (LNM) are recommended additional intestinal resection with lymph node dissection. However, around 90% of the patients without LNM are exposed to the risk of being overtreated due to the insufficient pathological criteria for risk stratification of LNM. Circulating tumor DNA (ctDNA) is a noninvasive biomarker for molecular residual disease and relapse detection after treatments including surgical and endoscopic resection of solid tumors. The CIRCULATE‐Japan project includes a large‐scale patient‐screening registry of the GALAXY study to track ctDNA status of patients with stage II to IV or recurrent CRC that can be completely resected. Based on the CIRCULATE‐Japan platform, we launched DENEB, a new prospective study, within the GALAXY study for patients with pT1 CRC who underwent complete local resection and were scheduled for additional intestinal resection with lymph node dissection based on the standard pathologic risk stratification criteria for LNM. The aim of this study is to explore the ability of predicting LNM using ctDNA analysis compared with the standard pathological criteria. The ctDNA assay will build new evidence to establish a noninvasive personalized diagnosis in patients, which will facilitate tailored/optimal treatment strategies for CRC patients.